drugset / Trial / NCT07061210
An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and efficacy of HRS-2189 combined with Adebrelimab and BP102 in the treatment of metastatic colorectal cancer
Timeline
- Start
- 2025-07-01
- Primary completion
- 2026-10-01
- Completion
- 2027-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | — |
| Subject | BP102 | Monoclonal antibody | — | — |
| Subject | HRS-2189 | Unknown | — | — |